PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION

By J. Oss, W. O. Z. Areba, W. Ackson, H. E. K. Lein, D. A. J. W. Ilber, D. A. S. C. Annom, J. Ames, P. Aubert, S. T. L. H. Iggins, M. B. Rown and 1 more. 2002

6,212 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/030aaffc202c6e2725b16b417a9c3ef9bad3b650

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. J. Cleland
3. J. Januzzi
4. T. Horwich
5. Bernard R. Chaitman
6. Joseph S. Alpert
7. L. Tavazzi
8. Rick A. Nishimura

Citations in the corpus

• Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. (2005, neutral): “ARB at last follow-up 152 (18) 145 (17) 144 (18)”
• ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, methodology): “ICD therapy is indicated to reduce the risk of SCD in 2 patient groups: patients whose LVEF is less than or equal to 40% as a result of prior MI and who have spontaneous NSVT and sustained monomorphic VT inducible by EP testing,(267) and patients whose LVEF is less than 30% as a result of an MI that”
• Catheter Ablation for Atrial Fibrillation with Heart Failure (2018, neutral): “Long-standing persistent (duration >1 year) 51 (28) 55 (30)”